RenovoRx Strengthens Its Scientific Advisory Board With The Appointment Of Pancreatic Cancer Expert Dr. Timothy Donahue

RenovoRx, Inc., a life sciences company focused on developing targeted oncology therapies and commercializing its FDA-cleared drug delivery device, RenovoCath®, has announced the appointment of Dr. Timothy Donahue to its Scientific Advisory Board (SAB). Dr. Donahue is a highly respected surgeon and expert in pancreatic diseases from the University of California, Los Angeles (UCLA).

Dr. Donahue serves as the Director of UCLA’s Agi Hirshberg Center for Pancreatic Diseases and Chief of the Division of Surgical Oncology at the David Geffen School of Medicine. He also holds the Garry Shandling Chair in Pancreatic Surgery and has a joint appointment in the Department of Molecular and Medical Pharmacology. His research program is dedicated to improving the management and treatment of pancreatic cancer through advanced clinical and scientific studies.

As a leading figure in pancreatic surgery, Dr. Donahue performs several complex procedures each week and directs UCLA’s high-volume clinical program, which combines extended induction therapy with surgical approaches for locally advanced and borderline resectable pancreatic cancer. His extensive experience in translational oncology and clinical research has helped shape new multidisciplinary treatment strategies for this challenging disease.

In addition to his clinical responsibilities, Dr. Donahue leads a research laboratory funded by the National Institutes of Health (NIH), focusing on identifying new and more effective treatment strategies for pancreatic cancer through detailed mechanistic studies.

Welcoming Dr. Donahue to the advisory board, Dr. Ramtin Agah, Chief Medical Officer and Founder of RenovoRx, said that his deep expertise and leadership in pancreatic surgery and translational oncology will play a vital role in guiding the company’s efforts. He emphasized that Dr. Donahue’s experience at UCLA, one of the leading centers for pancreatic disease, will help advance RenovoRx’s mission to develop localized therapies aimed at improving outcomes for patients with hard-to-treat cancers.

Dr. Donahue expressed enthusiasm about joining the advisory board, noting that RenovoRx’s drug delivery platform offers a unique and promising approach. He highlighted the company’s Trans-Arterial Micro-Perfusion (TAMP™) technology, which targets drugs directly to tumor sites to increase local concentration while potentially improving survival and quality of life for patients. Throughout his career, Dr. Donahue has held several leadership positions, including serving as President of the Society of University Surgeons and Chair of the Surgical Research Committee of the American College of Surgeons.